Biosimilar Cost Savings In Europe Beyond 25% Might Cull Sponsors, EGA Warned
Executive Summary
Trade association hears pricing discipline and differentiated products are keys to sustaining European biosimilars market even as it continues to grow.
You may also be interested in...
How US Can Learn From Biosimilar Implementation In EU
Differences in payer policies have limited the biosimilar opportunity in some EU nations; IMS report points to examples US should replicate or avoid as biosimilars are introduced domestically.
European Savings From Small-Molecule Generic Launches Likely To Tail Off
Encouraging use of generics is one of few policy measures over past decades to generate large savings for U.K.’s National Health Service, but time may be running out for European countries to make major savings from declining number of new small-molecule generics.
Biosimilar Guidances: Broader Populations Permitted; More Immunogenicity Requested
New draft Q&A and three final guidances from FDA offer pros and cons for sponsors of biosimilar applications.